Rein Therapeutics, Inc. Common Stock (RNTX)

• Market cap: $36.7M
• 1 day: -2.34%
• 5 days: -6.70%
• 1 month: -4.57%
• 3 months: -13.02%
• 6 months: -58.25%
• Year to date: -25.78%
• 1 year: -59.86%
• 5 years: -83.25%
• 10 years: -99.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Employees: 11

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

4.96% more ownership

Funds ownership: 21.25% [Q3] → 26.21% (+4.96%) [Q4]

3% less funds holding

Funds holding: 32 [Q3] → 31 (-1) [Q4]

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

20% less capital invested

Capital invested by funds: $16.3M [Q3] → $13.1M (-$3.22M) [Q4]